Document is current
Any future updates will be listed below
-
Authors
Mead, Benjamin E. http://orcid.org/0000-0001-7258-7777
Hattori, Kazuki http://orcid.org/0000-0002-5592-4257
Levy, Lauren http://orcid.org/0000-0002-4420-1993
Imada, Shinya
Goto, Norihiro
Vukovic, Marko
Sze, Daphne
Kummerlowe, Conner http://orcid.org/0000-0002-8641-2916
Matute, Juan D. http://orcid.org/0000-0002-1703-8115
Duan, Jinzhi http://orcid.org/0000-0001-9351-4956
Langer, Robert http://orcid.org/0000-0003-4255-0492
Blumberg, Richard S.
Ordovas-Montanes, Jose
Yilmaz, Ömer H. http://orcid.org/0000-0002-7577-4612
Karp, Jeffrey M. http://orcid.org/0000-0002-4752-7374
Shalek, Alex K. http://orcid.org/0000-0001-5670-8778
- License Information
-
More Information
Article History
Received: 5 August 2020
Accepted: 3 February 2022
First Online: 21 March 2022
Competing interests
: J.M.K. and R.L. hold equity in Frequency Therapeutics, a company that has an option to license IP generated by J.M.K. and R.L. and that may benefit financially if the IP is licensed and further validated. The interests of J.M.K. and R.L. were reviewed and are subject to a management plan overseen by their institutions in accordance with their conflict-of-interest policies. J.O.-M. reports compensation for consulting services with Cellarity and Hovione. A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Third Rock Ventures, Ochre Bio, FL82, Relation Therapeutics Limited, and Dahlia Biosciences. The other authors declare no competing interests.
